# US 2021/0277096 A1 · Anti-complement factor c1q antibodies and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0277096 A1
- Document ID: US20210277096A1
- Status: Published application
- Kind: A1
- Application number: 17/172,807
- Filed: 2021-02-10
- Published: 2021-09-09
- Earliest claimed: 2013-07-09
- Assignees: Annexon, Inc.
- Applicants: Annexon Inc.
- Inventors: Arnon Rosenthal; Michael Leviten
- Web page: https://patentgrep.com/patent/US20210277096A1

## CPC

- C07K 16/18: against material from animals or humans
- A61K 49/0004: {Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/06: Antianaemics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 16/40: against enzymes
- G01N 33/56966: {Animal cells}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2317/14: Specific host cells or culture conditions, e.g. components, pH or temperature
- C07K 2317/20: characterized by taxonomic origin
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/54: F(ab')2
- C07K 2317/55: Fab or Fab'
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/734: Complement-dependent cytotoxicity [CDC]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- G01N 2333/4716: Complement proteins, e.g. anaphylatoxin, C3a, C5a
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention provides anti-C1q antibodies and methods of using the same.

## Claims

### Claim at position 1

1-94. (canceled)

### Claim 95

A composition comprising an anti-C1q antibody, comprising:
(a) a light chain hypervariable region (HVR) comprising HVR-L1 comprising the amino acid sequence of SEQ ID NO:5, HVR-L2 comprising the amino acid sequence of SEQ ID NO:6, and HVR-L3 comprising the amino acid sequence of SEQ ID NO:7; and
(b) a heavy chain HVR comprising HVR-H1 comprising the amino acid sequence of SEQ ID NO:9, HVR-H2 comprising the amino acid sequence of SEQ ID NO:10, and HVR-H3 comprising the amino acid sequence of SEQ ID NO:11.

### Claim 96 (depends on 95)

The composition of claim 95, wherein the antibody comprises a light chain variable domain comprising at least about 85% homology to the amino acid sequence of SEQ ID NO:4.

### Claim 97 (depends on 96)

The composition of claim 96, wherein the antibody comprises a light chain variable domain comprising at least about 95% homology to the amino acid sequence of SEQ ID NO:4.

### Claim 98 (depends on 97)

The composition of claim 97, wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO:4.

### Claim 99 (depends on 95)

The composition of claim 95, wherein the antibody comprises a heavy chain variable domain comprising at least about 85% homology to the amino acid sequence of SEQ ID NO:8.

### Claim 100 (depends on 99)

The composition of claim 99, wherein the antibody comprises a heavy chain variable domain comprising at least about 95% homology to the amino acid sequence of SEQ ID NO:8.

### Claim 101 (depends on 100)

The composition of claim 100, wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:8.

### Claim 102 (depends on 95)

The composition of claim 95, wherein the antibody binds specifically to human C1q, mouse C1q, and rat C1q, or both human C1q and mouse C1q.

### Claim 103 (depends on 95)

The composition of claim 95, wherein the antibody has a dissociation constant (KD) for human C1q and mouse C1q less than about 30 nM.

### Claim 104 (depends on 95)

The composition of claim 95, wherein the antibody specifically binds to and inhibits a biological activity of C1q.

### Claim 105 (depends on 104)

The composition of claim 104, wherein the biological activity is (a) C1q binding to an autoantibody, (b) C1q binding to C1r, (c) C1q binding to C1s, (d) C1q binding to phosphatidylserine, (e) C1q binding to pentraxin-3, (f) C1q binding to C-reactive protein (CRP), (g) C1q binding to globular C1q receptor (gC1qR), (h) C1q binding to complement receptor 1 (CR1), (i) C1q binding to beta-amyloid, or (j) C1q binding to calreticulin.

### Claim 106 (depends on 104)

The composition of claim 104, wherein the biological activity is (a) activation of the classical complement activation pathway, (b) activation of antibody and complement dependent cytotoxicity, (c) CH50 hemolysis, (d) synapse loss, (e) B-cell antibody production, (f) dendritic cell maturation, (g) T-cell proliferation, (h) cytokine production, (i) microglia activation, (j) Arthus reaction, (k) phagocytosis of synapses or nerve endings, or (l) activation of complement receptor 3 (CR3/C3) expressing cells.

### Claim 107 (depends on 106)

The composition of claim 106, wherein CH50 hemolysis comprises human, mouse, and/or rat CH50 hemolysis.

### Claim 108 (depends on 106)

The composition of claim 106, wherein the antibody neutralizes at least 50%, at least 80%, or at least 90% of CH50 hemolysis.

### Claim 109 (depends on 106)

The composition of claim 106, wherein the antibody neutralizes at least 50% of CH50 hemolysis at a dose of less than 200 ng/ml, less than 100 ng/ml, less than 50 ng/ml, or less than 20 ng/ml.

### Claim 110 (depends on 95)

The composition of claim 95, wherein the antibody is a murine, humanized, or chimeric antibody.

### Claim 111 (depends on 95)

The composition of claim 95, wherein the antibody is of the IgG class.

### Claim 112 (depends on 111)

The composition of claim 111, wherein the antibody has an IgG1, IgG2, IgG3, or IgG4 isotype.

### Claim 113 (depends on 95)

The composition of claim 95, wherein the antibody is an antibody fragment.

### Claim 114 (depends on 113)

The composition of claim 113, wherein the antibody fragment is a Fab, F(ab′)2 or Fab′ fragment.
